NeoAdjuvant Therapy Trial for TNBC: Sacituzumab Govitecan + Pembrolizumab
The ADAPT-TN-IV trial will explore the efficacy of Sacituzumab Govitecan combined with Pembrolizumab in neoadjuvant therapy for TNBC.
Indication
Clinical and regulatory intelligence for Triple-Negative Breast Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.